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relates to communication. The training will be offered
utilizing a combination of education strategies including
web-based video and return demonstration with clinical
managers.
Evaluation: The trainingwill be evaluated using pre and post
measures of BMT nurses’ conﬁdence and conﬁdence in
providing psychosocial support to patients and families. Data
will be collected at baseline and at three and six months post
communication skills training.302
The Role of Occupational Therapy and Its Impact on
Quality of Life for the Pediatric Stem Cell Recipient
Alisha Nicole Pratt 1, Jill Marie Bakker 2. 1 OTPTTR, Cincinnati
Childrens Hospital Medical Center, Cincinnati, OH; 2 OT/PT/TR,
Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Clinical Question (in PICO format)
P (Population/Problem) Among school aged children (3-18
years of age) receiving a stem cell transplant (SCT)*
I (Intervention) Does occupational therapy intervention(s)
C (Comparison)
O (Outcome) Limit the negative affect of SCT on a patient’s
quality of life?
Target Population for the Recommendation (Inclusion /
Exclusion Criteria for the recommendation)
Preschool (3 years) to young adult (18 years) who are
admitted to an inpatient unit to undergo SCT in the protected
environment
Background / Purpose of BESt Development
SCT is a highly risky and aggressive therapeutic approach for
an assortment of formerly incurable malignancies, hemato-
logical disorders, genetic disorders, and metabolic storage
diseases that have evolved dramatically in the past 25 years,
advancing at a rapid pace as scientiﬁc discoveries are trans-
formed into pediatric clinical settings (Tanzi 2011 [1b]).
Throughout the evidence, it is understood that there are
three phases of SCT, which consist of pre-transplant, inpa-
tient hospitalization and post-transplant. This review focuses
on the acute, inpatient phase of SCT, including when the
patient is hospitalized in the protected environment (PE).
Evidence was reviewed with the objectives to delineate the
roles and responsibilities of the OT during the inpatient
phase of SCT, while also improving understanding of how the
role of OT can impact HRQOL.303
Determinants of Early and Late Transfusion Burden after
Hematopoietic Stem Cell Transplantation (HSCT): An
Analysis of 174 Transplant Recipients from a Single Center
Duncan Purtill 1, Annette Le Viellez 2, Julian P. Cooney 3,
Richard Herrmann 4, Matthew Wright 4, Paul Cannell 5.
1 Haematology Department, Royal Perth Hospital, Perth,
Australia; 2 Transfusion Laboratory, Royal Perth Hospital, Perth,
Australia; 3 Royal Perth Hospital Hem Dept, Perth, Australia;Transfusions between D0-D30
N patients
Disease stage: early vs intermediate vs advanced 42 vs 25 vs 106
Donor: ABO identical vs minor vs major incompatible 98 vs 33
vs 43
Donor: matched related vs unrelated 82 vs 90
Stem cell source: peripheral blood vs marrow vs cord blood 153 vs 14
vs 74 Department of Haematology, Royal Perth Hospital, Perth,
Australia; 5 Haematology, Royal Perth Hospital, Perth, Australia
Aim: Transfusion burden after HSCT in the modern era may
differ from that reported in the early literature regarding
bone marrow transplantation. We sought to quantify the red
cell (RC) and platelet transfusion burden associated with
HSCT at our center and to identify factors associated with
increased transfusions after transplant.
Methods: Patients were included who underwent ﬁrst
allogeneic HSCT at our center from 01/2004-12/2011. The
cumulative number of RC and platelet transfusions for each
patient was recorded at days 30, 90 and 365 post-transplant.
Products were transfused according to clinical need, usually
to maintain hemoglobin >80mg/dL and platelets >10x10e6/
L. Single donor apheresis platelets were used. Donor-recip-
ient pairs were ABO-identical, minor incompatible (donor
antibodies to recipient red cell RC) or major incompatible
(recipient antibodies to donor RC).
Results: 174 patients underwent HSCT for acute leukemia
(47%), other hematological malignancy (44%) or other diag-
nosis (3%) at amedian age of 42 years. Conditioning regimens
were myeloablative in 138 (80%) and reduced intensity in 34
(20%). A median of 12 (range 2-117) ABO group and antibody
screen assays were performed per patient between D0-D365.
All patients received at least one unit of either RC or platelets.
The median number of both RC and platelet units transfused
between D0-D30 was 4 each (range: 0-20 and 0-32 respec-
tively) and this was associated with patient and transplant
characteristics (Table). Post-transplant transfusions were not
inﬂuenced by recipient age, sex or conditioning regimen. Of
162 patients alive at day 31, 45 (28%) received RC and 37
(23%) platelet transfusions between D31-D90. Cord blood
recipients and those who developed grade 2-4 acute GVHD
were more likely to receive both RC (p ¼ 0.03 & p ¼ 0.01,
respectively) and platelets (p ¼ 0.005 & p ¼ 0.01) during this
period. After D90, relapse prior to D365 was the only factor
inﬂuencing both RC and platelet transfusions (p < 0.001 for
both).
Conclusion: The overall transfusion burden after allogeneic
HSCT at our center was lower than we expected. Patients
with advanced malignancies, ABO incompatible donors, and
unrelated or cord blood donors required more transfusions
early post-transplant, while GVHD and relapse were associ-
ated with transfusion after D30. These ﬁndings will inform
our clinical practice and assist the transfusion laboratory to
optimize cost-effectiveness and efﬁciency.304
Effects of Calcineurin Inhibitors on Urinary Sodium
Excretion Early after Allogenic Hematopoietic Stem Cell
Transplantation
Masuho Saburi, Takehiko Mori, Jun Kato, Yuya Koda,
Sumiko Kohashi, Shinichiro Okamoto. Division of Hematology,
Keio University School of Medicine, Tokyo, JapanRed cells (median units) P value Platelets (median units) P value
2 vs 5.5 vs 4 0.08 3 vs 4 vs 5 0.02
4 vs 6 vs 6 <0.001 4 vs 6 vs 4 0.15
4 vs 4.5 0.05 3 vs 5 0.003
4 vs 4 vs 11 0.003 4 vs 7
vs 16
<0.001
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A (CsA) and tacrolimus often cause renal dysfunction
resulting in an increase in serum creatinine (Cr), hyper-
kalemia, hypomagenesemia, and hyperuricemia. Electrolyte
and uric acid abnormalities are considered mainly due to
renal tubular impairment. However, the effects of CI on the
sodium regulation have yet to be fully evaluated. In the
present study, we have quantitatively evaluated the effects of
CI on urinary sodium excretion in patients receiving tar-
olimus or CsA in the early period after allogenetic hemato-
poietic stem cell transplantation (HSCT).
Patients and Methods: One hundred recipients of allogeneic
HSCT receiving CI (CsA, n¼50; tacrolimus, n¼50) with the
available weekly data for calculating fractional excretion of
sodium (FENa) for 4-week period after transplantation were
enrolled. No signiﬁcant differences were observed in patient
characteristics except for the type of donor between CsA and
tarolimus groups. FENa was calculated according to the
following formula: 100 x (Urinary sodium x Serum Cr)/
(Serum sodium x Urinary Cr).
Results: Both CsA and tarolimus groups showed increase in
FENa at 2nd to 4th weeks after transplantation as compared
with those at 1st week (0.960.44 for CsA; 0.920.49 for
tacrolimus). Among them, a signiﬁcant increase was only
observed at 3rd and 4th weeks in tacrolimus group, but not
in CsA group. In addition, FENawas signiﬁcantly higher at 4th
week in tacrolimus group as compared with CsA group
(1.601.12 vs. 1.130.80 :p<0.05).
Conclusion: These results suggest that urinary sodium
excretion increases under the administration of CI after
allogeneic HSCT probably through renal tubular impairment
and that there is a signiﬁcant difference in the renal tubular
toxicity between tacrolimus and CsA.305
Antibiotic Prophylaxis Therapy for Pediatric Patients
Undergoing Hematopoietic Stem Cell Transplant (HSCT):
A Tale of 2 Centers
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Introduction: Bacterial infections are a leading cause of
morbidity and treatment-related mortality in children
following hematopoietic stem cell transplant (HSCT). Meta-
analysis of studies of bacterial prophylaxis in adult oncology
patients with neutropenia showed a signiﬁcantly decreased
risk of death associated with prophylaxis regimens. How-
ever, the use of prophylaxis vs. empiric treatment is
controversial in the setting of HSCT and data in children is
limited. The concerns for using prophylaxis therapy are
development of antibiotic resistance and increased drug-
related toxicity. An empiric approach to antibiotic therapy
prompts the concern that therapy is delayed until an infec-
tion has already occurred. Our study aimed to compare the
bacteremia rates in two pediatric centers that use contrast-
ing approaches; empiric vs. prophylaxis.
Methods:Wecompared the incidenceof bacterial infections in
pediatric HSCT patients in two units; The Hospital for Sick
Children (SickKids) where an empiric antibiotic strategy is
utilized and Vanderbilt University Medical Center, where pro-
phylaxis antibiotic (Ceﬁpime) is givenwhen ANC<500/ul or on
the day of transplant, which ever is earlier. Baseline character-
isticswerecomparedbetween the2groupswith2sample tests,
where categorical variables and continuous variables were
evaluated using double-sided Fisher exact tests respectively.
Results: 224pediatricpatients fromSickKids and294pediatric
patients from Vanderbilt who underwent autologous and
allogeneic HSCTs between 2005-2010 were evaluated. Total
bacteremia rate (Gram positive and Gram negative) was
signiﬁcantly higher at SickKids (68/224) vs. Vanderbilt (49/
294), p<0.001). At SickKids,19% presented with Gram positive
infection as their ﬁrst infection at a mean of 8.9 d after trans-
plant and 11% with gram negative infection at a mean of 4.0
d after transplant.At Vanderbilt, 14% presented with gram
positive infectionatameanof9.5dafter transplant and2%with
gram negative infection at a mean of 5.2 d after transplant. No
treatment-relatedmortality in theﬁrst 100dayswasattributed
to bacterial infections in either center. Using a multivariable
model including: age, diagnosis (malignant vs. non-malignant)
and type of transplant ( allogeneic vs. autologous), only anti-
biotic prophylaxis approach resulted in a signiﬁcantly lower
gram negative bacteremia (p¼<0.001) and a trend toward
lower incidence of gram positive bacteremia (p¼0.052)..
